Medicare Enrolled
Dr. Wasif Riaz, M.D
Medical Oncology · Sebring, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Riaz from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Riaz? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Riaz
Dr. Wasif Riaz is a medical oncology in Sebring, FL, with 17 years in practice. Based on federal Medicare data, Dr. Riaz performed 240,961 Medicare services across 5,333 unique beneficiaries.
Between the years covered by Open Payments, Dr. Riaz received a total of $20,789 from 97 pharmaceutical and/or device companies across 1155 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Riaz is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years in practice▲ Top 9% volume in FL$ $20,789 industry payments
Medicare Practice Summary
Medicare Utilization ↗240,961
Medicare services
Top 9% in FL for medical oncology
5,333
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~14,174 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 51,000 | $0 | $4 |
| Iron sucrose injection (Venofer) | 50,900 | $0 | $5 |
| Filgrastim injection (Zarxio) for white blood cells | 30,360 | $0 | $2 |
| Anti-nausea injection (aprepitant) | 18,850 | $1 | $5 |
| Denosumab injection (Prolia/Xgeva) | 16,800 | $18 | $51 |
| Pembrolizumab injection (Keytruda) | 15,200 | $43 | $137 |
| Paclitaxel chemotherapy injection | 14,594 | $0 | $2 |
| Epoetin alfa injection (Procrit) for anemia | 9,320 | $6 | $23 |
| Immune globulin infusion (Gammagard) | 6,942 | $36 | $108 |
| Dexamethasone injection (steroid) | 4,296 | $0 | $3 |
| Complete blood count (CBC) with differential | 3,260 | $8 | $29 |
| Blood draw (venipuncture) | 2,851 | $8 | $9 |
| Office visit, established patient (30-39 min) | 2,226 | $94 | $339 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,950 | $1 | $28 |
| Drug injection, under skin or into muscle | 1,401 | $10 | $69 |
| Anti-nausea injection (ondansetron/Zofran) | 1,316 | $0 | $9 |
| Injection of additional new drug or substance into vein | 1,246 | $12 | $61 |
| Injection, leucovorin calcium, per 50 mg | 923 | $3 | $12 |
| Administration of chemotherapy into vein, 1 hour or less | 753 | $96 | $378 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 679 | $1 | $6 |
| Injection, fluorouracil, 500 mg | 640 | $2 | $7 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 559 | $47 | $189 |
| Injection, zoledronic acid, 1 mg | 498 | $7 | $69 |
| Injection, carboplatin, 50 mg | 450 | $2 | $41 |
| Injection, diphenhydramine hcl, up to 50 mg | 400 | $1 | $3 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 396 | $3 | $205 |
| Administration of chemotherapy into vein, each additional hour | 316 | $21 | $79 |
| Office visit, established patient (20-29 min) | 269 | $65 | $239 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 259 | $22 | $84 |
| Hospital follow-up visit, moderate complexity | 194 | $62 | $197 |
| Administration of additional new drug or substance into vein, 1 hour or less | 188 | $49 | $178 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 180 | $15 | $56 |
| Injection of drug or substance into vein | 165 | $28 | $156 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 160 | $3 | $11 |
| New patient office visit (45-59 min) | 150 | $117 | $453 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 149 | $55 | $206 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 138 | $26 | $89 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 123 | $136 | $562 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 112 | $17 | $59 |
| Infusion into a vein for hydration, each additional hour | 103 | $10 | $42 |
| Initial hospital admission, high complexity | 97 | $137 | $556 |
| Administration of additional new drug or substance into vein using push technique | 79 | $42 | $170 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 73 | $126 | $637 |
| Infusion, normal saline solution , 1000 cc | 71 | $2 | $7 |
| Automated urinalysis | 57 | $2 | $8 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 54 | $1 | $7 |
| Infusion into a vein for hydration, 31-60 minutes | 46 | $24 | $156 |
| New patient office visit, complex (60-74 min) | 38 | $173 | $585 |
| Drawing of blood for a medical problem | 34 | $65 | $277 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 33 | $4 | $15 |
| Injection, alteplase recombinant, 1 mg | 32 | $61 | $218 |
| Office visit, established patient, complex (40-54 min) | 19 | $140 | $474 |
| New patient office visit (30-44 min) | 12 | $78 | $298 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
24.6% high complexity
71.4% medium
4.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$20,789
Total received (2018-2024)
Avg $2,970/year across 7 years
Top 25% in FL for medical oncology
97
Companies
1,155
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$19,262 (92.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,526 (7.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$4,843
2023$4,496
2022$3,317
2021$2,491
2020$1,505
2019$2,213
2018$1,923
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,595
PFIZER INC.
$1,444
E.R. Squibb & Sons, L.L.C.
$1,437
Janssen Biotech, Inc.
$1,383
Celgene Corporation
$1,151
AstraZeneca Pharmaceuticals LP
$980
Astellas Pharma US Inc
$844
Seagen Inc.
$748
Amgen Inc.
$659
Lilly USA, LLC
$652
Genentech USA, Inc.
$643
Merck Sharp & Dohme LLC
$612
Gilead Sciences, Inc.
$554
Merck Sharp & Dohme Corporation
$504
GENZYME CORPORATION
$394
Incyte Corporation
$375
Daiichi Sankyo Inc.
$373
Eisai Inc.
$311
Alexion Pharmaceuticals, Inc.
$285
SOBI, INC
$258
BeiGene USA, Inc.
$225
Takeda Pharmaceuticals U.S.A., Inc.
$212
GlaxoSmithKline, LLC.
$206
ABBVIE INC.
$202
Boehringer Ingelheim Pharmaceuticals, Inc.
$194
Bayer HealthCare Pharmaceuticals Inc.
$180
Pharmacyclics LLC, An AbbVie Company
$174
Foundation Medicine, Inc.
$152
Clovis Oncology, Inc.
$141
Bayer Healthcare Pharmaceuticals Inc.
$137
Rigel Pharmaceuticals, Inc.
$135
Agios Pharmaceuticals, Inc.
$128
Seattle Genetics, Inc.
$127
AbbVie Inc.
$125
Regeneron Healthcare Solutions, Inc.
$124
PharmaEssentia USA Corporation
$121
TESARO, Inc.
$111
Karyopharm Therapeutics Inc.
$111
JAZZ PHARMACEUTICALS INC.
$111
ARRAY BIOPHARMA INC
$111
Mirati Therapeutics, Inc.
$110
Dendreon Pharmaceuticals LLC
$108
Myriad Genetic Laboratories, Inc.
$105
Deciphera Pharmaceuticals Inc.
$99
TerSera Therapeutics LLC
$87
SANOFI-AVENTIS U.S. LLC
$85
Taiho Oncology, Inc.
$84
Apellis Pharmaceuticals, Inc.
$82
Pharmacyclics LLC, an AbbVie Company
$72
G1 Therapeutics, Inc.
$71
PUMA BIOTECHNOLOGY, INC.
$69
Helsinn Therapeutics (U.S.), Inc.
$68
EISAI INC.
$64
Aveo Pharmaceuticals, Inc.
$63
Puma Biotechnology, Inc.
$62
Sobi, Inc
$57
EUSA Pharma (US) LLC
$54
Dova Pharmaceuticals
$53
GE HEALTHCARE
$52
ADC Therapeutics America, Inc.
$52
Stemline Therapeutics Inc.
$50
EMD Serono, Inc.
$49
Myovant Sciences Inc.
$47
AbbVie, Inc.
$45
CTI BioPharma Corp.
$45
Pharmacosmos Therapeutics Inc.
$44
Ipsen Biopharmaceuticals, Inc
$41
Epizyme, Inc.,
$39
TAIHO ONCOLOGY, INC.
$38
SERVIER PHARMACEUTICALS LLC
$37
Genmab U.S., Inc.
$37
MorphoSys, US Inc.
$35
Partner Therapeutics, Inc.
$35
Blueprint Medicines Corporation
$33
Kyowa Kirin, Inc.
$32
Secura Bio, Inc.
$31
AMAG Pharmaceuticals, Inc.
$28
AngioDynamics, Inc.
$27
Kite Pharma, Inc.
$26
Global Blood Therapeutics, Inc.
$26
Fennec Pharmaceuticals, Inc.
$25
Epizyme, Inc.
$23
Servier Pharmaceuticals LLC
$21
Adaptive Biotechnologies Corporation
$21
Menarini Silicon Biosystems, Inc.
$20
Exelixis Inc.
$20
Jazz Pharmaceuticals Inc.
$19
ImmunoGen, Inc.
$19
Sysmex Inostics Inc
$19
Advanced Accelerator Applications
$18
Heron Therapeutics, Inc.
$18
Acrotech Biopharma Inc.
$17
Alnylam Pharmaceuticals Inc.
$17
PROGENICS PHARMACEUTICALS, INC.
$17
CSL Behring
$16
Sumitomo Pharma America, Inc.
$16
Acceleron Pharma, Inc.
$13
Top 3 companies account for 21.5% of total payments
Associated products mentioned in payments ›
ABECMA · ADAKVEO · ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · ALUNBRIG · AYVAKIT · Alecensa · Aliqopa · Avastin · BELEODAQ · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · CABOMETYX · CALQUENCE · COSELA · CYRAMZA · Cellsearch · Columvi · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · ENJAYMO · ERBITUX · ERLEADA · EVENITY · Empaveli · Enhertu · Epkinly · Erleada · FARYDAK · FERAHEME · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · Farydak · GAVRETO · GAZYVA · GILOTRIF · GIVLAARI · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INFLECTRA · INLYTA · INQOVI · INREBIC · Idelvion · Imbruvica · Inrebic · JADENU · JAKAFI · JAYPIRCA · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Leukine · Lonsurf · Lutathera · MEKINIST · MONJUVI · MONOFERRIC · MVASI · MYLOTARG · MYRISK · Monoferric · NERLYNX · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Onivyde · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PROVENGE · PYLARIFY · PYRUKYND · Padcev · Pedmark · Perjeta · Phesgo · Pomalyst · Prolia · QINLOCK · REBLOZYL · RETEVMO · RYBREVANT · RYDAPT · Reblozyl · Revlimid · Rezlidhia · Rituxan · Rubraca · SANDOSTATIN · SANDOSTATIN LAR · SARCLISA · SCEMBLIX · SHINGRIX · SOLERO · SOMATULINE DEPOT · SPRYCEL · SUSTOL · SUTENT · Stivarga · Sylvant · TAGRISSO · TALVEY · TASIGNA · TAZVERIK · TECVAYLI · TEVIMBRA · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Tibsovo · Trodelvy · ULTOMIRIS · Ultomiris · VALCHLOR · VENCLEXTA · VERZENIO · VONJO · VONVENDI · VOTRIENT · Venclexta · Vonjo · Voranigo · XALKORI · XGEVA · XOSPATA · XPOVIO · XTANDI · Xofigo · Xtandi · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX · ZYTIGA · Zoladex · clonoSEQ · myChoice CDx · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (93%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $9 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
2
Per 100K population
1.9
County median income
$55,581
Nearest hospital
ADVENTHEALTH SEBRING
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Riaz is a mixed practice specialist, with above-average Medicare volume (top 9% in FL), and low-engagement industry engagement, with 17 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Riaz experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Riaz performed 51,000 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Riaz receive payments from pharmaceutical companies?
Yes. Dr. Riaz received a total of $20,789 from 97 companies across 1,155 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Riaz's costs compare to other medical oncologys in Sebring?
Dr. Riaz's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Riaz) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Sebring
Browse medical oncologys in Sebring ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in FL
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in FL
Which FL medical oncologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology